Management of Regional Lymph Nodes in Localized Vulvar Carcinoma

국소 외음부 암에서 영역 림프절의 치료

  • Jang, Won-Il (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Wu, Hong-Gyun (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Park, Charn-Il (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Ha, Sung-Whan (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Lee, Hyo-Pyo (Departments of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Kang, Soon-Beom (Departments of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Song, Yong-Sang (Institute of Radiation Medicine, Medical Research Center, Seoul National University)
  • 장원일 (서울대학교 의과대학 방사선종양학교실) ;
  • 우홍균 (서울대학교 의과대학 방사선종양학교실) ;
  • 박찬일 (서울대학교 의과대학 방사선종양학교실) ;
  • 하성환 (서울대학교 의과대학 방사선종양학교실) ;
  • 이효표 (서울대학교 의과대학 산부인과학교실) ;
  • 강순범 (서울대학교 의과대학 산부인과학교실) ;
  • 송용상 (서울대학교 의학연구원 방사선의학연구소)
  • Published : 2008.03.30

Abstract

Purpose: To evaluate the impact of postoperative radiotherapy on loco-regional failure in patients with vulvar carcinoma and to determine the treatment strategy for inguinal lymph nodes. Materials and Methods: Sixty-six patients who received treatment for primary vulvar carcinoma at Seoul National University Hospital, from October 1979 through June 2004, were retrospectively analyzed. Sixteen patients were excluded from the analysis due to the following reasons: distant metastases in two patients; palliative intent for six patients; previous radiotherapy given to the pelvis in three patients; follow-up loss after surgery for four patient; insufficient medical records for one patient. Of 50 eligible patients, 35 were treated with surgery alone(S), ten were treated with surgery followed by radiotherapy(S+RT), and five were treated with radiotherapy alone. Results: The 5-year overall survival(OS) and disease-free survival(DFS) rates of all patients were 91% and 78%, respectively. Twelve patients(26%) experienced treatment failures and the sites of initial failure were as follows: a primary site in eight patients; regional lymph nodes in three patients; the lung in one patient. Although risk factors for failure were more common in the S+RT group than the S group of patients(p<0.05), the DFS rates were similar for the two groups(5-year DFS rates, 78% vs. 83%, p=0.66). The incidences of occult lymph node metastases was 10%. Ten of 31 patients with clinically negative lymph nodes did not received inguinal lymph node dissection, but no patient experienced regional failure. Conclusion: Postoperative radiotherapy may have a potential benefit for patients with risk factors for failure. The omission of inguinal dissection or elective radiotherapy to the inguinal lymph nodes may be considered in low-risk patients with clinically negative lymph nodes.

목적: 외음부 암환자에서 국소영역 치료실패에 대한 수술 후 방사선치료의 영향을 평가하고 임상적으로 림프절이 전이가 없는 환자들에서 서혜부 림프절에 대한 치료방침을 결정해 보고자 하였다. 대상 및 방법: 1979년 10월부터 2004년 6월까지 서울대학교병원에서 일차성 외음부 암으로 치료를 받은 환자 66명에 대해 후향적 분석을 시행하였다. 이들 중에서 원격전이가 있는 2명, 고식적 목적으로 치료를 받은 6명, 이전에 골반부 위 방사선 치료의 병력이 있는 3명, 추적관찰이 탈락된 4명, 의무기록이 불충분한 1명을 포함하여 16명의 환자들은 이번 분석에서 제외되었다. 50 명 중에 수술만 받은 환자가 35명, 수술과 방사선 치료를 받은 환자가 10명, 방사선 치료만을 받은 환자가 5명이었다. 결과: 5년 전체 생존율과 무병 생존율은 각각 91%, 78%였다. 12명(26%)에서 치료 실패를 보였으며, 국소 실패가 8명, 영역림프절 전이가 3명, 원격 전이가 1명이었다. 수술과 방사선치료를 같이 받은 환자들이 수술만을 받은 환자들보다 위험요인을 더 많이 가지고 있었지만, 무병 생존율은 두 집단에서 통계적으로 유의한 차이를 보이지 않았다(5년 무병 생존율 78% vs. 83%, p=0.66). 잠재성 림프절 전이의 빈도는 10%였다. 임상적으로 림프절 전이가 없었던 31명의 환자들 중에서 10명은 서혜부 림프절 절제술을 받지 않았지만, 이들 중에서 영역림프절 전이를 경험한 사람은 아무도 없었다. 결론: 치료실패의 위험요인을 가진 외음부 암자들에게 수술 후 방사선 치료는 잠재적인 이점을 가지고 있다. 임상적으로 림프절 전이가 없는 위험도가 낮은 환자들에게는 서혜부 림프절 절제술을 하지 않는 것이나 서혜부 림프절에 대해 예방적 방사선치료를 하는 것에 대해서 고려해 볼 수 있겠다.

Keywords

References

  1. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995;75(Suppl. 1):270-294 https://doi.org/10.1002/1097-0142(19950101)75:1+<270::AID-CNCR2820751312>3.0.CO;2-D
  2. Hacker NF, Eifel P, McGuire WP, et al. Principles and practice of gynecologic oncology. Philadelphia, Lippincott Co. 1992:537-566
  3. Hacker NF, Van der Velden J. Conservative management of early vulvar cancer. Cancer 1993;71(Suppl. 4):1673-1677 https://doi.org/10.1002/cncr.2820710436
  4. de Hullu JA, Oonk MH, van der Zee AG. Modern management of vulvar cancer. Curr Opin Obstet Gynecol 2004;16:65-72 https://doi.org/10.1097/00001703-200402000-00012
  5. Iversen T, Aalders JG, Christensen A, Kolstad P. Squamous cell carcinoma of the vulva: a review of 424 patients, 1956-1974. Gynecol Oncol 1980;9:271-279 https://doi.org/10.1016/0090-8258(80)90038-4
  6. Podratz KC, Symmonds RE, Taylor WF. Carcinoma of the vulva: analysis of treatment failures. Am J Obstet Gynecol 1982;143:340-351 https://doi.org/10.1016/0002-9378(82)90823-7
  7. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991;164:997-1003 https://doi.org/10.1016/0002-9378(91)90573-A
  8. Podratz KC, Symmonds RE, Taylor WF, Williams TJ. Carcinoma of the vulva: analysis of treatment and survival. Obstet Gynecol 1983;61:63-74
  9. Morley GW. Infiltrative carcinoma of the vulva: results of surgical treatment. Am J Obstet Gynecol 1976;124:874-888 https://doi.org/10.1016/S0002-9378(16)33392-0
  10. Stehman FB, Bundy BN, Thomas G, Varia M, Okagaki T, Roberts J. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1992;24:389-396 https://doi.org/10.1016/0360-3016(92)90699-I
  11. Curry SL, Wharton JT, Rutledge F. Positive lymph nodes in vulvar squamous carcinoma. Gynecol Oncol 1980;9:63-67 https://doi.org/10.1016/0090-8258(80)90009-8
  12. Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol 1983;61:408-412
  13. Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW. Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys 1997;38:381-389 https://doi.org/10.1016/S0360-3016(97)82500-X
  14. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study) Gynecol Oncol 1993;49:279-283 https://doi.org/10.1006/gyno.1993.1127
  15. Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986;68:733-740
  16. Hutter RVP, Greene FL, Balch CM, Page DL, Haller DG, Fleming ID. AJCCcancer staging manual, 6th ed. New York: Springer-Verlag, 2002:243-249
  17. Perez CA, Grigsby PW, Chao C, Galakatos A, Garipagaoglu M, Mutch D. Irradiation in carcinoma of the vulva: factors affecting outcome. Int J Radiat Oncol Biol Phys 1998;42:335-344
  18. Knopp S, Holm R, Trope C, Nesland JM. Occult lymph node metastases in early stage vulvar carcinoma patients. Gynecol Oncol 2005;99:383-387 https://doi.org/10.1016/j.ygyno.2005.06.023
  19. Gonzalez Bosquet J, Kinney WK, Russell AH, Gaffey TA, Magrina JF, Podratz KC. Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2003;57:419-424 https://doi.org/10.1016/S0360-3016(03)00536-4
  20. McCall AR, Olson MC, Potkul RK. The variation of inguinal lymph node depth in adult women and its importance in planning elective irradiation for vulvar cancer. Cancer. 1995;75:2286-2288 https://doi.org/10.1002/1097-0142(19950501)75:9<2286::AID-CNCR2820750916>3.0.CO;2-G
  21. Petereit DG, Mehta MP, Buchler DA, Kinsella TJ. Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 1993;27:963-967 https://doi.org/10.1016/0360-3016(93)90475-B
  22. Katz A, Eifel PJ, Jhingran A, Levenback CF. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2003;57:409-418 https://doi.org/10.1016/S0360-3016(03)00591-1